The genomic and evolutionary landscapes of anaplastic thyroid carcinoma

Peter YF. Zeng(Western University), Stephenie D. Prokopec(Ontario Institute for Cancer Research), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Nicole Pinto(Western University), Michelle Chan‐Seng‐Yue(Ontario Institute for Cancer Research), Roderick Clifton‐Bligh(The University of Sydney), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Christopher J. Howlett(Western University), Paul Plantinga(Western University), Matthew J. Cecchini(Griffith University), Alfred K. Lam(Griffith University), Iram Siddiqui(Hospital for Sick Children), Jianxin Wang(Ontario Institute for Cancer Research), Ren Sun(Ontario Institute for Cancer Research), John D. Watson(Ontario Institute for Cancer Research), Reju Korah(Yale University), Tobias Carling(Yale University), Nishant Agrawal(University of Chicago), Nicole A. Cipriani(University of Chicago), Douglas W. Ball(Johns Hopkins University), Barry D. Nelkin(Johns Hopkins University), Lisa M. Rooper(Johns Hopkins University), Justin A. Bishop(The University of Texas Southwestern Medical Center), Cathie Garnis(BC Cancer Agency), Ken Berean(BC Cancer Agency), Norman G. Nicolson(Yale University), Paul Weinberger(Louisiana State University Health Sciences Center Shreveport), Ying C. Henderson(The University of Texas MD Anderson Cancer Center), Christopher M. Lalansingh(Ontario Institute for Cancer Research), Mao Tian(University of California, Los Angeles), Takafumi N. Yamaguchi(Ontario Institute for Cancer Research), Julie Livingstone(Ontario Institute for Cancer Research), Adriana Salcedo(Ontario Institute for Cancer Research), Krupal Patel(Ontario Institute for Cancer Research), Frederick S. Vizeacoumar(University of Saskatchewan), Alessandro Datti(Mount Sinai Hospital), Xi Liu(Baylor College of Medicine), Yuri E. Nikiforov(University of Pittsburgh Medical Center), Robert C. Smallridge(WinnMed), John A. Copland(Mayo Clinic in Florida), Laura A. Marlow(Mayo Clinic in Florida), Martin Hyrcza(McMaster University), Leigh Delbridge(The University of Sydney), Stan B. Sidhu(The University of Sydney), Mark Sywak(The University of Sydney), Bruce Robinson(The University of Sydney), Kevin Fung(Western University), Farhad Ghasemi(Western University), Keith Kwan(Western University), S. Danielle MacNeil(Western University), Adrian Mendez(Western University), David A. Palma(Western University), Mohammed Imran Khan(Western University), Mushfiq Hassan Shaikh(Western University), Kara M. Ruicci(Western University), Bret Wehrli(Western University), Eric Winquist(Western University), John Yoo(Western University), Joe S. Mymryk(Western University), James W. Rocco(The Ohio State University), David A. Wheeler(Baylor College of Medicine), Steve Scherer(Baylor College of Medicine), Thomas J. Giordano(University of Michigan), John W. Barrett(Western University), William C. Faquin(Harvard University), Anthony J. Gill(The University of Sydney), Gary L. Clayman(Tampa General Hospital), Paul C. Boutros(University of California, Los Angeles), Anthony C. Nichols(Western University)
Cell Reports
February 26, 2024
Cited by 70Open Access
Full Text

Abstract

Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA from 329 regions of thyroid cancer, including 213 from patients with primary anaplastic thyroid carcinomas. We also whole genome sequenced 9 patients using multi-region sequencing of both differentiated and anaplastic thyroid cancer components. Using these data, we demonstrate thatanaplastic thyroid carcinomas have a higher burden of mutations than other thyroid cancers, with distinct mutational signatures and molecular subtypes. Further, different cancer driver genes are mutated in anaplastic and differentiated thyroid carcinomas, even those arising in a single patient. Finally, we unambiguously demonstrate that anaplastic thyroid carcinomas share a genomic origin with co-occurring differentiated carcinomas and emerge from a common malignant field through acquisition of characteristic clonal driver mutations.


Related Papers

No related papers found

Powered by citation graph analysis